Copilot
Uw dagelijkse AI-companion
Ongeveer 520.000 resultaten
  1. Food and Drug Administration (.gov)
    https://www.fda.gov/drugs/resources-information-approved-drugs/fda...

    FDA grants accelerated approval to elranatamab-bcmm for multiple

    Ontdek verder

    Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
    pfizer.com
    Elranatamab: First Approval - PubMed
    pubmed.ncbi.nlm.nih.gov
    Elranatamab in relapsed or refractory multiple myeloma: …
    nature.com
    Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated …
    pfizer.com
    Elranatamab-bcmm - NCI
    cancer.gov
    Aanbevolen op basis van wat populair is • Feedback
  2. Nature
    https://www.nature.com/articles/s41591-023-02528-9

    Elranatamab in relapsed or refractory multiple myeloma: phase 2 ...

    Ontdek verder

    Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific …
    ashpublications.org
    Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in ... - …
    onclive.com
    Aanbevolen op basis van wat populair is • Feedback

  3. Afbeeldingen van Elranatamab Moa

    bing.com/images
    Alle afbeeldingen weergeven
  4. ASCO Publications
    https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.8014

    Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, …

    Ontdek verder

    Globaal webpictogram
    MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB …
    library.ehaweb.org
    Pfizer Reports Positive Clinical Data for BCMA-CD3 …
    pfizer.com
    Aanbevolen op basis van wat populair is • Feedback
  5. Nature
    https://www.nature.com/articles/s41591-023-02528-9.… · PDF-bestand

    Elranatamab in relapsed or refractory multiple myeloma: phase 2 ...

  7. Pfizer
    https://www.pfizer.com/news/press-release/press-release-detail/pfize…

    Pfizer’s Elranatamab Granted FDA Breakthrough Therapy …

  8. Nature
    https://www.nature.com/articles/s41591-023-02589-w

    Elranatamab in relapsed or refractory multiple myeloma: the

  9. Mensen vragen ook naar
    What is elranatamab?
    Provided by the Springer Nature SharedIt content-sharing initiative Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses.

    Elranatamab in relapsed or refractory multiple myeloma: phase 2

    nature.com
    Does elranatamab treat multiple myeloma?
    Nature Medicine 29 , 2570–2576 ( 2023) Cite this article Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy.

    Elranatamab in relapsed or refractory multiple myeloma: the ... - Nature

    nature.com
    What is elranatamab (pf-06863135)?
    Elranatamab (PF-06863135) is a humanized bispecific antibody that targets both BCMA (on myeloma cells) and CD3 (on T cells) 3. Elranatamab activates and directs T cells to induce a cytotoxic T-cell response against myeloma cells 10.

    Elranatamab in relapsed or refractory multiple myeloma: phase 2

    nature.com
    Is elranatamab a humanized B-cell maturation antigen (BCMA)-CD3 bispecific?
    Nature Medicine 29 , 2259–2267 ( 2023) Cite this article Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses.

    Elranatamab in relapsed or refractory multiple myeloma: phase 2

    nature.com
    Feedback
  10. American Society of Hematology
    https://ashpublications.org/blood/article/142/Supplement 1/3385/503…

    Long-Term Efficacy and Safety of Elranatamab Monotherapy in the …

  11. Pfizer
    https://www.pfizer.com/news/press-release/press-release-detail/pfize…

    Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 ...

  12. ASCO Publications
    https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8008

    Efficacy and safety of elranatamab in patients with …

  13. Pfizer
    https://www.pfizer.com/news/press-release/press-release-detail/pfize…

    Pfizer Presents Updated Favorable Elranatamab Data from Pivotal …